Incyte (INCY) announced the first clinical data evaluating its TGFbetaR2PD-1 bispecific antibody for patients with microsatellite stable, MSS, colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma, PDAC. The data were featured in two oral sessions at the European Society of Medical Oncology, ESMO, Congress 2025. INCA33890: Initial data showed promising clinical efficacy with INCA33890 treatment. This trial is ongoing, and the data will continue to mature. Of note: INCA33890 demonstrated a manageable safety profile across all enrolled patients – the occurrence and severity of immune related adverse reactions was similar to approved immune checkpoint inhibitors. Among patients with metastatic MSS colorectal cancer treated with INCA33890 at RDE, the vast majority had received more than two prior treatment regimens and 71.4% had active liver metastases at the time of treatment. INCB161734: Preliminary data demonstrated evidence of clinical benefit in advanced or metastatic PDAC patients treated with INCB161734. This trial is ongoing, and the data will continue to mature. Specifically: INCB161734 demonstrated a manageable safety profile across all treated patients. No DLTs were reported in dose escalation, and the maximum tolerated dose was not reached. No fatal adverse events were considered related to treatment. PDAC patients receiving 600 mg and 1,200 mg INCB161734 daily demonstrated objective response rates and high DCRs. The study is ongoing for the majority of patients; data on durability of response is expected in the first half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Bollinger, Credo, Ambarella, Cipher, Incyte: Insider Moves Unveiled!
- Early notable gainers among liquid option names on October 16th
- Promising Efficacy and Safety of Incyte’s Oncology Assets Justify Buy Rating
- Incyte announces results from its Phase 1 studies of INCA33890, INCB161734
- Ambarella, Planet Labs, Box, Conagra, Incyte: Major Stock Moves!